bertis24

[bertis24]

Exo-PASS Exosome Therapeutics Quality Control | BERTIS

BERTIS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis’ scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.

Exo-PASS Exosome Therapeutics Quality Control: Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package.

Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods.

Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years.

Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.

Click here to contact Bertis

View more: Exo-PASS Exosome Therapeutics Quality Control

[bertis24]

Proteomics-Based Blood Test Solution for the Early Diagnosis of Breast Cancer | BERTIS

BERTIS, a proteomics technology company that uses bioinformatics and proteomics to find key biomarkers for detecting cancers and various diseases. Bertis stands out in the field of quantitative proteomics with its comprehensive technology platform. They encompass the entire process, from identifying protein biomarkers to developing diagnostic solutions. This allows them to conduct in-depth research and development on diagnostic solutions for various cancers and major diseases.

Early diagnosis of Pancreatic Cancer

Pancreatic cancer is the worst cancer with a 5-year relative survival rate of only 11%. While effective early diagnostic methods for pancreatic cancer are currently lacking, BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample. Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer. Following algorithm development and validation, we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings. The number of deaths and new cases with pancreatic cancer are increasing every year worldwide and it is a fatal cancer in which the number of deaths per new cases in a year is significantly low when compared with other cancers.

Development Process The pancreas is located deep inside the body; behind the stomach, connected to the duodenum and bile ducts, adjacent to the spleen. This location makes pancreatic cancer difficult to detect and hence spreads quickly throughout the body. Nearly half of patients (52%) are diagnosed with pancreatic cancer in the distant metastasis stage when cancer cells have already spread to other organs. In this condition, the relative survival rate is only 3.1%. Early diagnosis is of the utmost importance with this cancer.

Click here to contact Bertis

View more: World’s First Proteomics-Based Blood Test Solution for the Early Diagnosis of Breast Cancer